JGP Global Gestao de Recursos Ltda. Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

JGP Global Gestao de Recursos Ltda. acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,233 shares of the biopharmaceutical company’s stock, valued at approximately $300,000. Alnylam Pharmaceuticals makes up approximately 0.4% of JGP Global Gestao de Recursos Ltda.’s portfolio, making the stock its 27th biggest holding.

Several other hedge funds have also recently bought and sold shares of ALNY. Truist Financial Corp acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $474,000. Gilbert & Cook Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 7.7% during the fourth quarter. Gilbert & Cook Inc. now owns 4,443 shares of the biopharmaceutical company’s stock worth $850,000 after purchasing an additional 317 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $71,000. Metis Global Partners LLC grew its holdings in shares of Alnylam Pharmaceuticals by 2.2% during the fourth quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock worth $839,000 after purchasing an additional 94 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 4.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 438,304 shares of the biopharmaceutical company’s stock worth $83,896,000 after purchasing an additional 19,324 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the sale, the chief executive officer now owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the sale, the chief executive officer now owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares in the company, valued at approximately $35,632. The disclosure for this sale can be found here. Insiders have sold a total of 103,148 shares of company stock valued at $25,658,824 over the last 90 days. 1.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on ALNY shares. UBS Group increased their target price on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a report on Friday, June 28th. Citigroup increased their target price on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Evercore ISI increased their target price on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, June 25th. BMO Capital Markets restated an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Finally, Wells Fargo & Company raised their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Seven analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $279.14.

Alnylam Pharmaceuticals Trading Down 0.3 %

NASDAQ:ALNY opened at $253.14 on Thursday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $287.55. The business’s 50-day moving average price is $257.19 and its two-hundred day moving average price is $189.87. The firm has a market capitalization of $32.02 billion, a price-to-earnings ratio of -94.46 and a beta of 0.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. The company’s revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.21) EPS. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.82 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.